Global Ovarian Cancer Diagnostics and Therapeutics 麻豆原创 Research Report 2023

Publication ID:

PB511232057

Publication Date:

November 1, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Ovarian cancer is often fatal because it is usually advanced when diagnosed. Symptoms are usually absent in early stages and nonspecific in advanced stages.The goal of treatment for ovarian cancer is to surgically remove as much of the cancer as possible through the debulking and then to provide what is called adjuvant, or additional therapy, such as chemotherapy, to kill any possibly remaining cancer cells in the body.
The global Ovarian Cancer Diagnostics and Therapeutics market is projected to reach US$ 2695.8 million in 2029, increasing from US$ 1811 million in 2022, with the CAGR of 5.4% during the period of 2023 to 2029.
This market is closely related to the pharmaceutical market.The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Ovarian Cancer Diagnostics and Therapeutics market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Astrazeneca
Boehringer Ingelheim
Bristol Myers Squibb
Eli Lilly
F. Hoffman-La Roche
Glaxosmithkline
Johnson & Johnson
Kazia Therapeutics
Siemens Healthineers
MSD
Clovis Oncology
Pfizer
Merck
Segment by Type
Diagnosis
Therapeutics
Segment by Application
Hospital
Medical Research Institute
Pharmaceuticals Companies
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Ovarian Cancer Diagnostics and Therapeutics report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. 麻豆原创 Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: 麻豆原创 Conclusions
Chapter 13: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Ovarian Cancer Diagnostics and Therapeutics 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Diagnosis
1.2.3 Therapeutics
1.3 麻豆原创 by Application
1.3.1 Global Ovarian Cancer Diagnostics and Therapeutics 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Medical Research Institute
1.3.4 Pharmaceuticals Companies
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Ovarian Cancer Diagnostics and Therapeutics 麻豆原创 Perspective (2018-2029)
2.2 Ovarian Cancer Diagnostics and Therapeutics Growth Trends by Region
2.2.1 Global Ovarian Cancer Diagnostics and Therapeutics 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Ovarian Cancer Diagnostics and Therapeutics Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Ovarian Cancer Diagnostics and Therapeutics Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Ovarian Cancer Diagnostics and Therapeutics 麻豆原创 Dynamics
2.3.1 Ovarian Cancer Diagnostics and Therapeutics Industry Trends
2.3.2 Ovarian Cancer Diagnostics and Therapeutics 麻豆原创 Drivers
2.3.3 Ovarian Cancer Diagnostics and Therapeutics 麻豆原创 Challenges
2.3.4 Ovarian Cancer Diagnostics and Therapeutics 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Ovarian Cancer Diagnostics and Therapeutics Players by Revenue
3.1.1 Global Top Ovarian Cancer Diagnostics and Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Ovarian Cancer Diagnostics and Therapeutics Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Ovarian Cancer Diagnostics and Therapeutics 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Ovarian Cancer Diagnostics and Therapeutics Revenue
3.4 Global Ovarian Cancer Diagnostics and Therapeutics 麻豆原创 Concentration Ratio
3.4.1 Global Ovarian Cancer Diagnostics and Therapeutics 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Ovarian Cancer Diagnostics and Therapeutics Revenue in 2022
3.5 Ovarian Cancer Diagnostics and Therapeutics Key Players Head office and Area Served
3.6 Key Players Ovarian Cancer Diagnostics and Therapeutics Product Solution and Service
3.7 Date of Enter into Ovarian Cancer Diagnostics and Therapeutics 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Ovarian Cancer Diagnostics and Therapeutics Breakdown Data by Type
4.1 Global Ovarian Cancer Diagnostics and Therapeutics Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Ovarian Cancer Diagnostics and Therapeutics Forecasted 麻豆原创 Size by Type (2024-2029)
5 Ovarian Cancer Diagnostics and Therapeutics Breakdown Data by Application
5.1 Global Ovarian Cancer Diagnostics and Therapeutics Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Ovarian Cancer Diagnostics and Therapeutics Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Ovarian Cancer Diagnostics and Therapeutics 麻豆原创 Size (2018-2029)
6.2 North America Ovarian Cancer Diagnostics and Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Ovarian Cancer Diagnostics and Therapeutics 麻豆原创 Size by Country (2018-2023)
6.4 North America Ovarian Cancer Diagnostics and Therapeutics 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Ovarian Cancer Diagnostics and Therapeutics 麻豆原创 Size (2018-2029)
7.2 Europe Ovarian Cancer Diagnostics and Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Ovarian Cancer Diagnostics and Therapeutics 麻豆原创 Size by Country (2018-2023)
7.4 Europe Ovarian Cancer Diagnostics and Therapeutics 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Ovarian Cancer Diagnostics and Therapeutics 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Ovarian Cancer Diagnostics and Therapeutics 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Ovarian Cancer Diagnostics and Therapeutics 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Ovarian Cancer Diagnostics and Therapeutics 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Ovarian Cancer Diagnostics and Therapeutics 麻豆原创 Size (2018-2029)
9.2 Latin America Ovarian Cancer Diagnostics and Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Ovarian Cancer Diagnostics and Therapeutics 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Ovarian Cancer Diagnostics and Therapeutics 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Ovarian Cancer Diagnostics and Therapeutics 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Ovarian Cancer Diagnostics and Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Ovarian Cancer Diagnostics and Therapeutics 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Ovarian Cancer Diagnostics and Therapeutics 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Astrazeneca
11.1.1 Astrazeneca Company Detail
11.1.2 Astrazeneca Business Overview
11.1.3 Astrazeneca Ovarian Cancer Diagnostics and Therapeutics Introduction
11.1.4 Astrazeneca Revenue in Ovarian Cancer Diagnostics and Therapeutics Business (2018-2023)
11.1.5 Astrazeneca Recent Development
11.2 Boehringer Ingelheim
11.2.1 Boehringer Ingelheim Company Detail
11.2.2 Boehringer Ingelheim Business Overview
11.2.3 Boehringer Ingelheim Ovarian Cancer Diagnostics and Therapeutics Introduction
11.2.4 Boehringer Ingelheim Revenue in Ovarian Cancer Diagnostics and Therapeutics Business (2018-2023)
11.2.5 Boehringer Ingelheim Recent Development
11.3 Bristol Myers Squibb
11.3.1 Bristol Myers Squibb Company Detail
11.3.2 Bristol Myers Squibb Business Overview
11.3.3 Bristol Myers Squibb Ovarian Cancer Diagnostics and Therapeutics Introduction
11.3.4 Bristol Myers Squibb Revenue in Ovarian Cancer Diagnostics and Therapeutics Business (2018-2023)
11.3.5 Bristol Myers Squibb Recent Development
11.4 Eli Lilly
11.4.1 Eli Lilly Company Detail
11.4.2 Eli Lilly Business Overview
11.4.3 Eli Lilly Ovarian Cancer Diagnostics and Therapeutics Introduction
11.4.4 Eli Lilly Revenue in Ovarian Cancer Diagnostics and Therapeutics Business (2018-2023)
11.4.5 Eli Lilly Recent Development
11.5 F. Hoffman-La Roche
11.5.1 F. Hoffman-La Roche Company Detail
11.5.2 F. Hoffman-La Roche Business Overview
11.5.3 F. Hoffman-La Roche Ovarian Cancer Diagnostics and Therapeutics Introduction
11.5.4 F. Hoffman-La Roche Revenue in Ovarian Cancer Diagnostics and Therapeutics Business (2018-2023)
11.5.5 F. Hoffman-La Roche Recent Development
11.6 Glaxosmithkline
11.6.1 Glaxosmithkline Company Detail
11.6.2 Glaxosmithkline Business Overview
11.6.3 Glaxosmithkline Ovarian Cancer Diagnostics and Therapeutics Introduction
11.6.4 Glaxosmithkline Revenue in Ovarian Cancer Diagnostics and Therapeutics Business (2018-2023)
11.6.5 Glaxosmithkline Recent Development
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Detail
11.7.2 Johnson & Johnson Business Overview
11.7.3 Johnson & Johnson Ovarian Cancer Diagnostics and Therapeutics Introduction
11.7.4 Johnson & Johnson Revenue in Ovarian Cancer Diagnostics and Therapeutics Business (2018-2023)
11.7.5 Johnson & Johnson Recent Development
11.8 Kazia Therapeutics
11.8.1 Kazia Therapeutics Company Detail
11.8.2 Kazia Therapeutics Business Overview
11.8.3 Kazia Therapeutics Ovarian Cancer Diagnostics and Therapeutics Introduction
11.8.4 Kazia Therapeutics Revenue in Ovarian Cancer Diagnostics and Therapeutics Business (2018-2023)
11.8.5 Kazia Therapeutics Recent Development
11.9 Siemens Healthineers
11.9.1 Siemens Healthineers Company Detail
11.9.2 Siemens Healthineers Business Overview
11.9.3 Siemens Healthineers Ovarian Cancer Diagnostics and Therapeutics Introduction
11.9.4 Siemens Healthineers Revenue in Ovarian Cancer Diagnostics and Therapeutics Business (2018-2023)
11.9.5 Siemens Healthineers Recent Development
11.10 MSD
11.10.1 MSD Company Detail
11.10.2 MSD Business Overview
11.10.3 MSD Ovarian Cancer Diagnostics and Therapeutics Introduction
11.10.4 MSD Revenue in Ovarian Cancer Diagnostics and Therapeutics Business (2018-2023)
11.10.5 MSD Recent Development
11.11 Clovis Oncology
11.11.1 Clovis Oncology Company Detail
11.11.2 Clovis Oncology Business Overview
11.11.3 Clovis Oncology Ovarian Cancer Diagnostics and Therapeutics Introduction
11.11.4 Clovis Oncology Revenue in Ovarian Cancer Diagnostics and Therapeutics Business (2018-2023)
11.11.5 Clovis Oncology Recent Development
11.12 Pfizer
11.12.1 Pfizer Company Detail
11.12.2 Pfizer Business Overview
11.12.3 Pfizer Ovarian Cancer Diagnostics and Therapeutics Introduction
11.12.4 Pfizer Revenue in Ovarian Cancer Diagnostics and Therapeutics Business (2018-2023)
11.12.5 Pfizer Recent Development
11.13 Merck
11.13.1 Merck Company Detail
11.13.2 Merck Business Overview
11.13.3 Merck Ovarian Cancer Diagnostics and Therapeutics Introduction
11.13.4 Merck Revenue in Ovarian Cancer Diagnostics and Therapeutics Business (2018-2023)
11.13.5 Merck Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Astrazeneca
Boehringer Ingelheim
Bristol Myers Squibb
Eli Lilly
F. Hoffman-La Roche
Glaxosmithkline
Johnson & Johnson
Kazia Therapeutics
Siemens Healthineers
MSD
Clovis Oncology
Pfizer
Merck

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.